Key Points
- EVP Andrew Polovin sold 12,874 shares on Nov. 24 at $75 for $965,550 and, including sales on Nov. 18–19, has disposed of about 24,466 shares for roughly $1.74 million, a move that trimmed his stake by 10.69% to 107,590 shares (≈$8.07M).
- Tempus AI beat Q3 estimates with EPS of ($0.11) and revenue of $334.21M (up 84.7% YoY), but remains unprofitable (negative ROE and net margin); analysts' consensus is a Hold with a $80.75 target.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) EVP Andrew Polovin sold 12,874 shares of Tempus AI stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $75.00, for a total value of $965,550.00. Following the sale, the executive vice president directly owned 107,590 shares in the company, valued at approximately $8,069,250. This trade represents a 10.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Andrew Polovin also recently made the following trade(s):
- On Wednesday, November 19th, Andrew Polovin sold 6,387 shares of Tempus AI stock. The shares were sold at an average price of $68.06, for a total value of $434,699.22.
- On Tuesday, November 18th, Andrew Polovin sold 5,205 shares of Tempus AI stock. The stock was sold at an average price of $65.54, for a total value of $341,135.70.
Tempus AI Price Performance
Shares of NASDAQ:TEM opened at $76.84 on Wednesday. The firm has a market capitalization of $13.67 billion, a PE ratio of -64.57 and a beta of 4.86. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $104.32. The business's 50 day moving average is $83.25 and its 200-day moving average is $72.40.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $334.21 million during the quarter, compared to analyst estimates of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.Tempus AI's revenue was up 84.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.46) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current year.
Institutional Investors Weigh In On Tempus AI
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock valued at $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC grew its stake in shares of Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Tempus AI by 0.4% during the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock valued at $117,523,000 after purchasing an additional 5,375 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock valued at $102,869,000 after purchasing an additional 965,730 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in Tempus AI by 6.4% in the 3rd quarter. AQR Capital Management LLC now owns 904,872 shares of the company's stock worth $73,032,000 after purchasing an additional 54,692 shares during the last quarter. Institutional investors own 24.22% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. BTIG Research lifted their target price on shares of Tempus AI from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Tuesday. Cowen cut shares of Tempus AI from a "buy" rating to a "hold" rating in a research report on Tuesday, October 21st. TD Cowen lowered shares of Tempus AI from a "buy" rating to a "hold" rating and set a $88.00 price target on the stock. in a research report on Tuesday, October 21st. Piper Sandler decreased their price objective on shares of Tempus AI from $105.00 to $80.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 11th. Finally, Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $110.00 to $95.00 and set a "buy" rating for the company in a report on Wednesday, November 5th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $80.75.
Get Our Latest Stock Report on TEM
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
